Genetic Products Differentially Expressed In Tumors And The Use Thereof

Abstract

The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.

1 .- 27 . (canceled) 
     
     
         28 . A purified antibody or an antigen binding fragment thereof that is capable of specifically binding to a tumor-associated antigen that is expressed or abnormally expressed on a cell, said tumor-associated antigen being selected from the group consisting of: (a) a tumor-associated antigen comprising the amino acid sequence of SEQ ID NO: 16; and (b) a tumor-associated antigen encoded by a nucleic acid comprising SEQ ID NO: 7, wherein said purified antibody binds to a deglycosylated form of the tumor-associated antigen. 
     
     
         29 . The purified antibody of  claim 28  that is a monoclonal, chimeric, or humanized antibody. 
     
     
         30 . A conjugate between the purified antibody or an antigen binding fragment thereof of  claim 28  and at least one therapeutic agent. 
     
     
         31 . The conjugate of  claim 30 , wherein said therapeutic agent is a toxin. 
     
     
         32 . The conjugate of  claim 30 , wherein said therapeutic agent is selected from the group consisting essentially of aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubin, doxorubicin, taxol, etoposide, fluorouracil, interferon-α, lomustine, mercaptopurine, methotrexate, mitotane, procarbazine hydrochloride, thioguanine, vinblastine sulfate, and vincristine sulfate. 
     
     
         33 . A pharmaceutical composition, comprising the purified antibody or antigen binding fragment thereof of  claim 28  and a pharmaceutically compatible carrier. 
     
     
         34 . The pharmaceutical composition of  claim 33 , wherein the purified antibody causes induction of cell death, reduction in cell growth, cell membrane damage, or secretion of cytokines. 
     
     
         35 . The pharmaceutical composition of  claim 34 , wherein said purified antibody is a complement-activating antibody, a monoclonal antibody, a chimeric antibody, or a humanized antibody. 
     
     
         36 . The pharmaceutical composition of  claim 34 , wherein said purified antibody is coupled to a therapeutic agent. 
     
     
         37 . The pharmaceutical composition of  claim 36 , wherein said therapeutic agent is a toxin. 
     
     
         38 . The pharmaceutical composition of  claim 36 , wherein said therapeutic agent is selected from the group consisting essentially of aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubin, doxorubicin, taxol, etoposide, fluorouracil, interferon-α, lomustine, mercaptopurine, methotrexate, mitotane, procarbazine hydrochloride, thioguanine, vinblastine sulfate and vincristine sulfate. 
     
     
         39 . A method of treating a cancer disease characterized by expression or abnormal expression of a tumor-associated antigen, comprising administering to a patient having said cancer disease an effective amount of the pharmaceutical composition of  claim 33 . 
     
     
         40 . The method of  claim 39 , wherein the cancer disease is selected from the group consisting of esophageal cancer, stomach cancer, gastric carcinoma, liver cancer, and ear, nose and throat (ENT) cancer. 
     
     
         41 . The method of  claim 39 , wherein said antibody or an antigen binding fragment thereof is coupled to a therapeutic agent. 
     
     
         42 . The method of  claim 41 , wherein said therapeutic agent is a toxin. 
     
     
         43 . The method of  claim 42 , wherein said therapeutic agent is selected from the group consisting essentially of aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubin, doxorubicin, taxol, etoposide, fluorouracil, interferon-α, lomustine, mercaptopurine, methotrexate, mitotane, procarbazine hydrochloride, thioguanine, vinblastine sulfate, and vincristine sulfate. 
     
     
         44 . The method of  claim 39 , wherein said purified antibody is a complement-activating antibody, a monoclonal antibody, a chimeric antibody, or a humanized antibody. 
     
     
         45 . The method of  claim 39 , wherein said purified antibody causes induction of cell death, reduction in cell growth, cell membrane damage, or secretion of cytokines.